CP
ABBV icon

Covenant Partners’s AbbVie ABBV Stock Holding History

Covenant Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,377
Closed -$1.46M – 2
2025
Q4 		$1.46M Buy
6,377
+26
+0.4% +$5.92K 0.43% 23
2025
Q3 		$1.47M Hold
6,351
– – 0.42% 29
2025
Q2 		$1.18M Hold
6,351
– – 0.35% 32
2025
Q1 		$1.33M Sell
6,351
-2,827
-31% -$550K 0.43% 27
2024
Q4 		$1.63M Sell
9,178
-135
-1% -$24.8K 0.5% 24
2024
Q3 		$1.84M Buy
9,313
+135
+1% +$25.2K 0.54% 23
2024
Q2 		$1.57M Hold
9,178
– – 0.48% 23
2024
Q1 		$1.67M Hold
9,178
– – 0.49% 23
2023
Q4 		$1.42M Hold
9,178
– – 0.45% 28
2023
Q3 		$1.37M Hold
9,178
– – 0.5% 24
2023
Q2 		$1.24M Hold
9,178
– – 0.45% 27
2023
Q1 		$1.46M Hold
9,178
– – 0.56% 18
2022
Q4 		$1.48M Hold
9,178
– – 0.6% 22
2022
Q3 		$1.23M Sell
9,178
-1,761
-16% -$253K 0.6% 23
2022
Q2 		$1.68M Hold
10,939
– – 0.78% 16
2022
Q1 		$1.77M Sell
10,939
-54
-0.5% -$7.84K 0.71% 18
2021
Q4 		$1.49M Hold
10,993
– – 0.55% 31
2021
Q3 		$1.19M Hold
10,993
– – 0.47% 45
2021
Q2 		$1.24M Hold
10,993
– – 0.47% 38
2021
Q1 		$1.19M Sell
10,993
-1,199
-10% -$128K 0.47% 37
2020
Q4 		$1.31M Buy
12,192
+630
+5% +$60.5K 0.55% 32
2020
Q3 		$1.01M Sell
11,562
-620
-5% -$58.4K 0.49% 36
2020
Q2 		$1.2M Buy
12,182
+396
+3% +$34.9K 0.55% 26
2020
Q1 		$898K Buy
11,786
+3,354
+40% +$286K 0.48% 37
2019
Q4 		$747K Buy
+8,432
New +$700K 0.35% 63
2019
Q3 		– Sell
-7,917
Closed -$576K – 177
2019
Q2 		$576K Buy
7,917
+1,593
+25% +$125K 0.31% 85
2019
Q1 		$510K Buy
+6,324
New +$517K 0.28% 93

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Covenant Partners's ABBV Position: Q1 2026 in Review

Covenant Partners sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 6,377 shares — an estimated $1.46M sold.

Covenant Partners first reported a position in ABBV in Q1 2019 and held it in 27 quarters. The position peaked at $1.84M in Q3 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Covenant Partners reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • Covenant Partners sold 6,377 AbbVie shares in Q1 2026, an estimated $1.46M.
  • Covenant Partners first reported a position in AbbVie in Q1 2019 and held it in 27 quarters.
  • Covenant Partners's AbbVie position peaked at $1.84M in Q3 2024.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Covenant Partners's 13F filing for Q1 2026.